DSIP: natural brain peptide linked to sleep and stress control
A small naturally occurring brain signal peptide, first found in 1977, that appears to shape sleep patterns and calm the body's stress response; experimental, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
FDA-tracked compound — synthesized for clinical/research use
Fork this card to add platform evidence →
FDA-tracked (reclassified Category 1, Feb 2026) — preclinical/clinical bioassay data exists
Fork this card to add platform evidence →
What this is
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring 9-amino-acid neuropeptide first isolated in 1977 by Marcel Monnier and colleagues at the University of Basel. The original experiment: electrical stimulation of the thalamus in donor rabbits induced a delta-wave sleep state, and cerebral venous blood dialyzed from those animals into freely moving recipients shifted the recipients toward delta-rich EEG patterns. The active fraction was purified, sequenced, and named for the EEG signature it produced (Schoenenberger and Monnier 1977).
Despite its name, DSIP is better understood as a multifunctional neuroendocrine modulator than as a sleep-inducing agent in the sedative-hypnotic sense. It has been studied in sleep-architecture, HPA axis, opioid, and pain contexts across a research program that ran from the late 1970s through the 1990s. No primary receptor has been confirmed after nearly five decades of investigation. Pharmaceutical development was discontinued by the late 1990s; the compound now exists primarily as a research tool and research-chemical product.
History
DSIP's origin is part of the foundational lore of sleep neuroscience. In 1977, Monnier's group at the University of Basel published the full characterization and amino acid sequence — Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu — alongside the synthesis of the nonapeptide and five possible metabolic fragments (Schoenenberger and Monnier 1977). The discovery arrived at a moment when endogenous sleep regulators were being actively sought, and it triggered a cluster of clinical trials across the late 1970s and 1980s covering chronic insomnia, narcolepsy, opioid and alcohol withdrawal, chronic pain, and stress modulation.
Results were mixed. Some insomnia trials showed EEG-level sleep-architecture effects; others found no difference from placebo. The withdrawal-support line produced what the literature describes as one of the more consistent clinical clusters, but it was never translated into a mainstream regulated therapy. By the late 1990s, mainstream pharmaceutical interest had largely ended. Some clinical use persisted in Russian and Eastern European settings, including the Deltaran formulation for withdrawal applications. The compound remained a subject of ongoing basic research — appearing in preclinical stroke-recovery and high-altitude cognition studies well into the 2010s — but no new Western clinical development program has been initiated.
What it does
DSIP modulates how the brain organizes sleep, particularly the slow electrical waves (delta waves) and sleep spindles measured by EEG. In clinical studies of chronic insomnia patients, it produced measurable changes in sleep architecture — including higher alertness during the day and a more compact sleep period in some participants — without acting as a sedative or reliably inducing sleep onset the way a benzodiazepine or z-drug would. It is not a drug that makes you feel drowsy; it appears to work at a more subtle, regulatory level in the brain's sleep-wake system.
Beyond sleep, DSIP interacts with multiple neuroendocrine systems. Studies in humans and animals have shown effects on stress-hormone release (ACTH and cortisol), pain perception, and opioid-related physiology. These multi-system effects are why the research community eventually came to see DSIP as a broad neuroendocrine modulator rather than a targeted sleep peptide. Its plasma half-life is very short — minutes — yet functional effects in some clinical studies persist for hours, a pattern consistent with engagement of downstream signaling cascades rather than sustained receptor occupancy.
Evidence
- Human: Multiple clinical trials in chronic insomnia patients from the 1980s documented EEG sleep-architecture changes — increased delta-wave activity and modulation of sleep spindles — in some cohorts, with other trials finding no significant difference from placebo. An open clinical trial demonstrated reduction of opioid withdrawal symptoms. Separate clinical trials examined DSIP in alcohol withdrawal and in chronic pain (single pilot study). Randomized controlled trials showed suppression of plasma ACTH after intravenous DSIP in some protocols; other RCTs found no significant effect on CRH-induced ACTH or cortisol secretion. A 2009 RCT found that DSIP used as an adjunct to isoflurane anaesthesia altered bispectral index (EEG), heart rate variability, and prevented very deep BIS levels. Clinical observations linked decreased plasma DSIP levels to patients with Cushing syndrome, who also showed reduced delta sleep. The entire human evidence base originates from the 1980s–1990s, was produced by a small set of European and Eastern European research groups, and has not been replicated under modern polysomnographic standards or contemporary diagnostic criteria.
- Animal: The original delta-sleep induction in rabbits was replicated across multiple studies. Preclinical rodent work demonstrated antinociceptive effects after central administration, reduction of CRF-induced corticosterone release, inhibition of somatostatin release via a dopaminergic mechanism, and anti-stress effects. A rodent focal-stroke study found improvement in motor function recovery. A high-altitude rat model found that a phosphorylated DSIP analog restored spatial memory and p-CREB expression by improving sleep architecture.
- In vitro: No in vitro bioactivity data identified in available sources.
Known effects
- EEG sleep-architecture modulation (delta-wave and spindle activity) — Emerging; demonstrated in multiple 1980s human clinical trials; results inconsistent across studies; no modern replication
- Opioid and alcohol withdrawal symptom reduction — Emerging; clinical trial evidence from historical Eastern European programs; not developed into a modern first-line application
- ACTH suppression (neuroendocrine) — Emerging; demonstrated in some human RCTs; null results in others for CRH-induced and meal-induced ACTH/cortisol endpoints
- Analgesic effect — Preliminary; single chronic-pain clinical pilot study; not independently replicated
- Stroke recovery (motor function) — Preliminary; preclinical rodent model only
- Antinociception — Preclinical; demonstrated after central administration in rodents
- Anti-stress and corticosterone modulation — Preclinical; demonstrated in rodent models
Safety signals
Adverse events in the clinical literature are sparse. The 1980s–1990s trial record describes DSIP as generally well-tolerated; mild drowsiness is the most commonly mentioned effect. No serious adverse events attributed to DSIP were identified in the clinical literature available. Occasional vivid or altered dream patterns appear in community reports but are not systematically documented in trials.
Long-term safety has not been established. Published clinical protocols were short-course — days to a few weeks. Chronic daily use over months has not been studied. Theoretical concerns exist regarding sustained perturbation of the HPA axis and opioid system, neither of which has been characterized at extended exposures.
Theoretical additive effects with benzodiazepines, z-drugs, and dual orexin receptor antagonists have been noted based on overlapping sleep-architecture modulation mechanisms; no controlled interaction data exist in clinical studies.
DSIP is a biologically unstable peptide unusually sensitive to degradation. Research-chemical preparations vary substantially in purity, peptide identity, and remaining biological activity; without third-party analytical testing, products from different suppliers are not reliably equivalent.
No human reproductive, teratogenicity, pediatric, or breastfeeding safety data have been published.
Regulatory status
- US (FDA): Not approved for any indication. Emideltide (DSIP) was removed from the FDA 503A category 2 nominations list (April 22, 2026; nominations withdrawn); the FDA intends to consult the PCAC on July 24, 2026 regarding Emideltide acetate and Emideltide free base. Compounding is not currently authorized pending PCAC action. Not a controlled substance.
- EU (EMA): Not approved as a medicine.
- UK (MHRA): No license.
- Canada: Not approved.
- Australia (TGA): Not approved; active enforcement against unapproved peptide sales has been reported.
- Russia / Eastern Europe: Clinical use persists in select settings via the Deltaran formulation for withdrawal applications; this is reported clinical use, not an equivalence to major-regulator approval.
- WADA: Not currently named on the WADA Prohibited List per available sources. WADA's S0 "non-approved substances" clause may apply given the absence of major-regulator approval; athletes subject to anti-doping bodies should seek specific guidance.
Myths and misconceptions
"DSIP is a sedative that puts you to sleep like a sleeping pill." DSIP modulates sleep architecture rather than acting as a sedative-hypnotic. The clinical literature describes effects on EEG patterns and sleep-stage distribution, not consistent acute sedation. The published evidence explicitly addresses this as a common misconception.
"DSIP is well-validated for insomnia." DSIP was studied in human clinical trials for insomnia during the 1980s, but results were mixed and pharmaceutical development was discontinued. It is not a validated insomnia treatment by modern evidence-based standards. The studies that exist are decades old, methodologically heterogeneous, and have not been replicated in contemporary trials.
"Because DSIP is naturally occurring in the body, it is safe to use indefinitely." Endogenous origin is not a safety property. Endogenous DSIP exists at tightly regulated, low concentrations as part of complex circadian and stress signaling. Bolus exogenous administration in non-physiologic patterns has not been characterized for long-term safety.
"DSIP is FDA-approved or in active clinical development." It is neither. Pharmaceutical development was effectively discontinued by the late 1990s. DSIP is not in active Western clinical development.
Open questions
- Modern clinical replication — the core insomnia and withdrawal findings from the 1980s have not been evaluated using contemporary polysomnographic standards, diagnostic criteria, or current blinding methodology
- Receptor identification — no primary receptor or binding partner has been confirmed after approximately 50 years of investigation; the molecular basis of DSIP's physiological effects remains uncharacterized
- Route equivalence — the clinical evidence base used intravenous administration; subcutaneous pharmacokinetics and bioequivalence in humans have not been established
- Long-term safety — no systematic chronic-use data exist; theoretical concerns about HPA axis and opioid system effects at extended exposures remain uncharacterized
- Responder prediction — no clinical or biological predictor of response has been identified; community response patterns appear variable
- Comparative efficacy — DSIP has not been formally compared with modern sleep agents such as z-drugs, dual orexin receptor antagonists, or melatonin receptor agonists
Mechanism
DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; MW 848.8 Da) modulates multiple neuroendocrine systems in parallel. No single primary receptor has been confirmed despite approximately five decades of investigation. Proposed mechanisms documented in the literature include:
- Sleep architecture modulation — promotes delta-wave activity and modulates sleep spindle patterns in EEG; receptor-level mechanism not established
- HPA axis modulation — influences ACTH and cortisol secretion; human RCTs show ACTH reduction in some protocols but no effect on CRH-induced ACTH or cortisol in others; results are not convergent
- GABAergic and glutamatergic involvement — GABA and glutamate signaling pathways implicated; receptor-level mechanism uncharacterized
- Opioid system interaction — influences pain perception and opioid withdrawal physiology; potential agonistic activity at opiate receptors has been proposed but confirmed receptor binding has not been established
- Serotonergic modulation — involvement in serotonin neurotransmission described; functional role in clinical effects not established
- Dopaminergic involvement — inhibition of somatostatin release via a dopaminergic mechanism demonstrated in preclinical work
DSIP's plasma half-life is very short (minutes), with endogenous peptide apparently existing in plasma partly bound to a protective carrier protein or as a component of higher-molecular-weight precursors, which may account for the discrepancy between its rapid clearance and the persistence of some observed effects. Splitting off the N-terminal Trp residue appears to lead to peptide inactivation.
Related peptides
- Selank — synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin; studied for anxiolytic and nootropic effects via GABAergic and serotonergic modulation; shares the neuroendocrine-modulator lineage with DSIP
- Semax — synthetic ACTH(4–7) analog with C-terminal PGP extension; studied for neuroprotective and nootropic effects; shares involvement in HPA-axis neuroendocrine signaling contexts explored for DSIP
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
If the peptide disappears from the bloodstream in minutes, why do its effects last for hours?
If a smaller, more stable fragment is doing the actual work, it could explain decades of confusing DSIP research results and point scientists toward a cleaner, longer-lasting drug candidate that is far easier to develop than the original peptide.
Could a peptide that rebuilds normal deep sleep help stroke patients recover memory and thinking faster?
Post-stroke patients frequently suffer both broken sleep and cognitive decline, and today there is little treatment for either. If this hypothesis holds, a peptide that normalizes sleep architecture, rather than simply sedating patients, could help the brain consolidate and repair itself, offering a genuinely new approach for an undertreated problem.
Could this naturally occurring peptide reduce the anxiety and craving that make quitting opioids or alcohol so brutal?
Withdrawal symptoms are one of the biggest barriers to recovery from opioid and alcohol addiction. If DSIP damps down the same brain stress pathway that newer addiction drugs are targeting, it might offer a fast-acting, body-friendly option, possibly alongside existing treatments, for people going through detox.
What if a drug only lowered cortisol when it was dangerously high, and left your everyday stress system completely alone?
Most stress and anxiety treatments blunt the whole system, which creates side effects and dependency risks. If DSIP turns out to work only on runaway stress, it could be a much safer long-term option for people with conditions like chronic anxiety or burnout, because it would not interfere with the healthy stress responses the body needs.
Could one targeted change to the peptide's structure make it survive in the body long enough to actually be useful as a medicine?
DSIP's main obstacle as a drug is that the body breaks it down almost immediately. If attaching a phosphate group to a single amino acid is enough to block that breakdown without changing how the peptide behaves, it could be one of the simplest routes from a promising research molecule to a real clinical treatment for sleep and stress disorders.
If just one end of this peptide is responsible for its action, could chemists build smaller, tougher molecules that do the same job?
Pinpointing the exact part of DSIP that binds to its target would give drug designers a precise blueprint for building smaller, more stable compounds that mimic its effects without being rapidly destroyed in the bloodstream, potentially opening a practical path to new sleep and stress medicines.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| ranking score | 0.7309596538543701 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | none_monomer |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-23 |
▸citationbibtex
@peptide{pep00007,
sequence = {WAGGDASGE},
target = {neuroprotective},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}